LiveMetric receives FDA 510(ok) for watch-like blood strain monitor

LiveMetric introduced it has acquired FDA 510(ok) clearance for its watch-like blood strain monitor, LiveOne.

The cuffless gadget makes use of a sensor array positioned over the radial artery to supply a strain waveform. The waveform is then analyzed by an algorithm to find out systolic and diastolic blood strain and pulse price. In accordance with the FDA’s 510(ok) database, LiveOne is meant for use in medical settings for sufferers 27 years and older with a palpable radial pulse.

The Luxembourg-based firm stated the LiveOne monitoring service will quickly be accessible by way of well being methods, insurers and self-insured employers for individuals with hypertension or cardiovascular ailments.

“The LiveOne gadget is meant to fight the worldwide epidemic of hypertension by providing sufferers and suppliers significant, deeply customized well being info so motion may be taken in real-time,” Kelly Benning, vice chairman of LiveMetric, stated in an announcement. 

“With the identical ease as carrying a watch, the LiveOne gadget will change how hypertension and heart problems are managed and handled by providing individuals a radical understanding of how their life-style, habits and drugs impression their blood strain. We’re targeted on bringing this to thousands and thousands of customers throughout the channels of our customer-base.”


One other firm behind a watch-like blood strain gadget is Aktiia, which introduced it had acquired a European CE mark in early 2021. The Swiss startup landed $17.5 million in Sequence A funding in November. Although it is not accessible commercially within the U.S. but, Aktiia introduced in January it might be conducting a examine with Brigham and Girls’s Hospital in Boston.

Omron Healthcare first acquired FDA clearance for its HeartGuide wearable blood strain monitor in 2018.

In the meantime, Samsung has included blood strain monitoring into its Galaxy smartwatches in international locations the place it has regulatory approval. Although ECG monitoring has been cleared by the FDA, blood strain monitoring is not accessible within the U.S. 

Apple can be inquisitive about blood strain monitoring for its Watch. Nevertheless, as Bloomberg reported in April, the know-how is not anticipated to be prepared till 2024, on the earliest. 

Supply hyperlink

What's your reaction?

In Love
Not Sure

You may also like

More in:Health

Leave a reply

Your email address will not be published. Required fields are marked *